Although the risk estimate for adiponectin was lower for KRAS-mutated CRC compared to the other subtypes (OR per 1 SD increase (95% CI): 0.81 (0.64, 1.03) for KRAS-mutated, 0.97 (0.78, 1.22) for BRAF-mutated, and 0.97 (0.84, 1.11) for double wild type, Fig. 4A), none differed significantly from 1, and there was no significant heterogeneity in risk estimates between subtypes (Pheterogeneity = 0.46). Here, ADIPOQ is linked to colorectal carcinoma.